

DAFTAR PUSTAKA

1. Aboltins, C. A., Dowsey, M. M., Buising, K. L., Peel, T. N., Daffy, J. R., Choong, P. F. M., & Stanley, P. A. (2010). Gram-negative prosthetic joint infection treated with debridement , prosthesis retention and antibiotic regimens including a fluoroquinolone. *European Society of Clinical Infectious Diseases*, 17(6), 862–867. <https://doi.org/10.1111/j.1469-0691.2010.03361.x>
2. Aggarwal, V. K., Bakhshi, H., Ecker, N. U., Gehrke, T., & Kendoff, D. (2014). Organism Profile in Periprosthetic Joint Infection : Pathogens Differ at Two Arthroplasty Infection Referral Centers in Europe and in the United States. *J Knee Surg*, 27, 399–406. Barena E. G., Section I "Chapter 2: Infection", in Blom, A. et al. (2018) Apley & Solomon's System of Orthopaedics and Trauma. Boca Raton, FL: CRC Press. pp. 31-61
3. Bernard L, Arvieux C, Brunschweiler B, Touchais S, Ansart S, Bru JP, et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. *N Engl J Med*. 2021;384(21):1991-2001. doi:10.1056/NEJMoa2020198.
4. Cahill, J. et al. (2008) 'Quality of life after infection in total joint replacement', *Journal of Orthopaedic Surgery*, 16(1), pp. 58–65. doi:10.1177/230949900801600115.
5. Casenaz A, Piroth L, Labattut L, Sixt T, Magallon A, Guilloteau A, et al. Epidemiology and antibiotic resistance of prosthetic joint infections according to time of occurrence: a 10-year study. *J Infect*. 2022;85(5):492-498. doi:10.1016/j.jinf.2022.07.009.
6. Chang Y, Li Y. Pathogenic bacteria characteristics and drug resistance in acute , delayed , and chronic periprosthetic joint infection : A retrospective analysis of 202 patients. *Int Wound J* 2023;3315–23. <https://doi.org/10.1111/iwj.14212>
7. Chen M, Chang C, Hu C, Wu Y, Chang Y. Periprosthetic Joint Infection Caused by Gram-Positive Versus Gram-Negative Bacteria : Lipopolysaccharide , but not Lipoteichoic Acid , Exerts Adverse Osteoclast-Mediated Effects on the Bone. *J Clin Med* 2019;8:1289.
8. Chalmers, B. P., Weston, J. T., Osmon, D. R., Berry, D. J., & Abdel, M. P. (2019). Prior hip or knee prosthetic joint infection in another joint increases risk three-fold of prosthetic joint infection after primary total knee arthroplasty. *Bone Joint J*, 101(7), 91–97. <https://doi.org/10.1302/0301-620X.101B7.BJJ-2018-1189.R1>
9. Coskun B, Uzun E, Sarıyılmaz K, Acar N, Günaydın B. What is the rate of antimicrobial resistance of a prosthetic joint infection in a major orthopaedic centre? *Antibiotics (Basel)*. 2024;13(4):306. doi:10.3390/antibiotics13040306.

10. Cullen GD, Salinas JL, Furukawa D. A Retrospective Cohort Study of Early Prosthetic Joint Infections at a US Academic Medical Center (2014-2023). *Cureus* 2025;17:1–12. <https://doi.org/10.7759/cureus.87744>.
11. Datta, A. (2025). Incidence and Management of Post-Arthroplasty Joint Infections. *International Journal of Pharmaceutical Quality Assurance*, 16(9), 94–99. <https://doi.org/10.25258/ijpqa.16.9.17>
12. Deconinck L, Dinh A, Nich C, Tritz T, Matt M, et al. (2019) Efficacy of cotrimoxazole (Sulfamethoxazole-Trimethoprim) as a salvage therapy for the treatment of bone and joint infections (BJIs). *PLOS ONE* 14(10): e0224106. <https://doi.org/10.1371/journal.pone.0224106>
13. Dragosloveanu S, Popescu R, Neagu R, et al. Microbiological profiles, antibiotic susceptibility patterns and the role of multidrug-resistant organisms in patients diagnosed with periprosthetic joint infection over 8 years: single-center observational cohort from Romania. *Microorganisms*. 2025;13(5):1168.
14. Ekhtiari S, Mai F, Karlidag T, Gehrke T, Citak M. Microbiological Differences Among Age Groups in Patients Diagnosed With Periprosthetic Joint Infection: A Database Analysis of 2,392 Patients. *J Am Acad Orthop Surg* 2025;33:313–8.
15. Espindola, R., Vella, V., Benito, N., Mur, I., Tedeschi, S., Rossi, N., Hendriks, J. G. E., Sorlí, L., Murillo, O., Scarborough, M., Scarborough, C., Kluytmans, J., Ferrari, M. C., Pletz, M. W., Mcnamara, I., Escudero-sanchez, R., Arvieux, C., Praena, J., Ustianowski, A., ... Rodríguez-ban, J. (2022). Preoperative and perioperative risk factors , and risk score development for prosthetic joint infection due to *Staphylococcus aureus* : a multinational matched case-control study. *Clinical Microbiology and Infection Journal*, 28. <https://doi.org/10.1016/j.cmi.2022.05.010>
16. Ferrari MC, Fischbacher A, Casana M, Gasol B, Pérez-Prieto D, Borens O. Multicentre retrospective observational study of gram-negative periprosthetic joint infections. *Orthop Proc* 2021.
17. Fröschen FS, Randau TM, Franz A, Molitor E. Microbiological Profiles of Patients with Periprosthetic Joint Infection of the Hip or Knee. *Diagnostics* 2022;12:1–11.
18. Fröschen FS, Randau TM, Franz A, Molitor E, Hischebeth GTR. Microbiological trends and antibiotic susceptibility patterns in patients with periprosthetic joint infection of the hip or knee over 6 years. *Antibiotics (Basel)*. 2022;11(9):1244. doi:10.3390/antibiotics11091244.
19. Haraldsdóttir I, Moore E, Taylor A, et al. Changing incidence, aetiology and outcomes of prosthetic joint infections: a population-based analysis 2006–2021. *J Clin Med*. 2025;14(15):5289. doi:10.3390/jcm14155289.

20. Hiddema JS, Chb MB, Sa FCO, Toit ALJ, Chb MB, Sa FCO, et al. Periprosthetic joint infection : A South African perspective. *SAMJ* 2023;113:1213–9
21. Hilmy, F. et al. (2020) 'Prosthetic joint infection microorganism pattern and risk factor profile: A single center study', *The Hip and Knee Journal*, 1(1), pp. 28–35. doi:10.46355/hipknee.v1i1.24.
22. Izakovicova, P., Borens, O. and Trampuz, A. (2019) 'Periprosthetic joint infection: Current concepts and outlook', *EFORT Open Reviews*, 4(7), pp. 482–494. doi:10.1302/2058-5241.4.180092.
23. Jiang G, Wang W, Yang Y, Zhang M, Yang Y, Jiang Q. Organism profiles and empirical treatments for periprosthetic joint infections. *J Orthop Surg Res* 2025;4:698.
24. Karlsen ØE, Borgen P, Bragnes B, Figved W, Grøgaard B, Rydinge J, et al. Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial. *J Orthop Surg Res.* 2020;15:365. doi:10.1186/s13018-020-01877-2.
25. Kim K, Zhu M, Coleman B, Munro JT, Young SW. Differing microorganism profile in early and late prosthetic joint infections following primary total knee arthroplasty—implications for empiric antibiotic treatment. *J Arthroplasty.* 2022;37(9):1858-1864.e1. doi:10.1016/j.arth.2022.04.015.
26. Karczewski D, Scholz J, Hipfl C, Akgün D, Gonzalez MR, Hardt S. Gram negative periprosthetic hip infection : nearly 25 % same pathogen infection persistence at a mean of 2 years. *Arch Orthop Trauma Surg* 2024;144:5053–9. <https://doi.org/10.1007/s00402-023-05104-5>.
27. Kristensen NK, Gundtoft PH, Elmengaard B, Pedersen AB, Lange J. Increased mortality following periprosthetic joint infection after total knee arthroplasty: a microbiologically verified nationwide cohort of 916 cases. *J Arthroplasty.* 2025;Epub ahead of print. doi:10.1016/j.arth.2025.05.117.
28. Lamagni, T. (2014) 'Epidemiology and burden of prosthetic joint infections', *Journal of Antimicrobial Chemotherapy*, 69(suppl 1), pp. i5–i10. doi:10.1093/jac/dku247.
29. Lenguerrand E, Whitehouse MR, Beswick AD, Kunutsor SK, Foguet P, Porter M, et al. Risk factors associated with revision for prosthetic joint infection following knee replacement : an observational cohort study from England and Wales. *Lancet Infect Dis* 2019;19:589–600. [https://doi.org/10.1016/S1473-3099\(18\)30755-2](https://doi.org/10.1016/S1473-3099(18)30755-2)
30. Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al. Oral versus intravenous antibiotics for bone and joint infection (OVIVA). *N Engl J Med.* 2019;380(5):425-436. doi:10.1056/NEJMoa1710926.

31. Li Y, Wuermanbieke S, Wang F, Mu W, Ji B, Guo X, et al. Efficacy and safety of intra-articular-only meropenem after one-stage revision for treating *Escherichia coli* -induced periprosthetic joint infection in a rat model. *Bone Jt Res* 2024;13:546–58. <https://doi.org/10.1302/2046-3758.1310.BJR-2024-0119.R1>.
32. Lora-Tamayo J, Senneville E, Oussedik S, Ferry T, Wouthuyzen-Bakker M, Tande AJ, et al. Appropriate duration of antimicrobial treatment for periprosthetic joint infections. *Antibiotics (Basel)*. 2024;13(4):293. doi:10.3390/antibiotics13040293.
33. Lowik CAM, Zijlstra WP, Knobben BAS, Ploegmakers JJW, Dijkstra B, Vries AJ de, et al. Obese patients have higher rates of polymicrobial and Gram-negative early periprosthetic joint infections of the hip than non-obese patients. *PLoS One* 2019;14:1–11
34. Ma T, Lyu J, Ma J, Huang X, Chen K, Wang S, et al. Comparative analysis of pathogen distribution in patients with fracture - related infection and periprosthetic joint infection : a retrospective study. *BMC Musculoskelet Disord* 2023:1–11. <https://doi.org/10.1186/s12891-023-06210-6>.
35. McLaren A.C., Michael A., Saubolle., Edwin Yu., Feltis Timothy.,(2024) Chapter 7: ‘The Microbiologic and Histopathologic Diagnosis of Orthopaedic Infections’ in Wongworawat, M.D., *Orthopaedic knowledge update®: Musculoskeletal infection*. AAOS.
36. McNally, M. et al. (2021) ‘The EBJIS definition of periprosthetic joint infection’, *The Bone & Joint Journal*, 103-B(1), pp. 18–25. doi:10.1302/0301-620x.103b1.bjj-2020-1381.r1.
37. McQueen M. M., "Chapter 29: Osteomyelitis and Other Orthopaedic Infections", in Tornetta, P., Ostrum R. F., McKee M. D., (2025) *Rockwood and Green’s fractures in adults*. 10th ed. Philadelphia: Wolters Kluwer. pp, 895-914
38. Migliorini F, Weber CD, Bell A, Betsch M, Maffulli N, Poth V. Bacterial pathogens and in - hospital mortality in revision surgery for periprosthetic joint infection of the hip and knee : analysis of 346 patients. *Eur J Med Res* 2023:1–7. <https://doi.org/10.1186/s40001-023-01138-y>.
39. Natasha, A., Wahid, M. and Sudarmono, P. (2021) ‘The current trend for prosthetic joint infection diagnosis from culture to molecular: A literature review’, *Journal of Clinical Microbiology and Infectious Diseases*, 1(1), pp. 24–27. doi:10.51559/jcmid.v1i1.6.
40. Ortega-Pena S, Colín-Castro C, Hernández-Duran M, López-Jácome E, Franco-Cendejas R. Microbiological characteristics and patterns of resistance in prosthetic joint infections in a referral hospital. *Cir Cir* 2015;83:371

41. Osmon, D.R. and Hanssen D., A. (2009) Chapter 14: 'Prosthetic Joint Infections', in Wongworawat, M.D. Orthopaedic knowledge update®: Musculoskeletal infection. AAOS.
42. Pannu, T.S., Villa, J.M. and Higuera, C.A. (2021) 'Diagnosis and management of infected arthroplasty', SICOT-J, 7, p. 54. doi:10.1051/sicotj/2021054.
43. Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, et al. The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria. *J Arthroplasty*. 2018;33(5):1309-1314.e2. doi:10.1016/j.arth.2018.02.078.
44. Peng H, Zhou Z, Wang F, Yan S. Microbiology of Periprosthetic Hip and Knee Infections in Surgically Revised Cases from 34 Centers in Mainland China. *Infect Drug Resist* 2021;14:2411–8.
45. Pulido, L. et al. (2008) 'Periprosthetic joint infection: The incidence, timing, and predisposing factors', *Clinical Orthopaedics & Related Research*, 466(7), pp. 1710–1715. doi:10.1007/s11999-008-0209-4.
46. Ramos MS, Benyamini B, Kompala V, et al. Periprosthetic joint infection mortality after total hip arthroplasty is comparable to 5-year rates of common cancers: a meta-analysis. *J Arthroplasty*. 2025;Epub ahead of print. doi:10.1016/j.arth.2025.04.036.
47. Rhatomy,MD, S. et al. (2024) 'Biofilms: Microbial communities and their crucial impact on healthcare', *The Hip and Knee Journal*, 5(1), pp. 1–2. doi:10.46355/hipknee.v5i1.157.
48. Rizaldy, M. K. (2025). The Triad of Risk: Advanced Age, Female Gender, and High BMI in Patients Requiring Total Knee Replacement for Osteoarthritis at a Tertiary Indonesian Hospital. *Bioscientia Medicina: Journal of Biomedicine & Translational Research*, 2364–2381.
49. Sarfraz A, Bussey-sutton C, Ronan EM, Khury F, Bosco JA, Schwarzkopf R, et al. Incidence of PJI in Total Knee Arthroplasty Patients Following Expanded Gram-Negative Antibiotic Prophylactic Protocol. *Microorganisms* 2025;13:1–10.
50. Sanctis J De, Teixeira L, Duin D Van, Odio C, Hall G, Tomford JW, et al. Complex prosthetic joint infections due to carbapenemase-producing *Klebsiella pneumoniae* : a unique challenge in the era of untreatable. *Int J Infect Dis* 2014;25:73–8. <https://doi.org/10.1016/j.ijid.2014.01.028>.
51. Scigliano, N. M., Carender, C. N., Glass, N. A., Deberg, J., & Bedard, N. A. (2020). Operative time and risk of surgical site infection and periprosthetic joint infection : a systematic review and meta-analysis. *The Iowa Orthopedic Journal*.
52. Singh TA, Singh KJK. Epidemiology and Antibiotic Resistance Pattern of Prosthetic Joint Infections : A Cross-Sectional Study. *Int J Pharm Res Technol* 2025;15:1093–101. <https://doi.org/10.31838/ijprt/15.01.169>.

53. Suliman, J., Warda, H. and Samaan, M. (2024) 'Review of recent advances in the diagnosis and management of periprosthetic joint infection after total knee arthroplasty part 2: Single-stage or two-stage surgical technique?', *Journal of Orthopaedic Surgery and Research*, 19(1). doi:10.1186/s13018-024-05152-6.
54. Tang Y, Fu B, Tong Q. Pathogen Distribution , Drug Resistance , and Postoperative High-Quality Nursing Intervention Effectiveness in Knee Osteoarthritis Patients After Knee Arthroplasty With Postoperative Infection. *J Multidiscip Healthc Open* 2025:891–902.
55. Tekin-taş, Z., Özger, H. S., Kanatlı, U., & Hızıl, K. (2024). The Incidence and Risk Factors of Early Periprosthetic Joint Infections. *Infect Dis Clin Microbiol*, 6(2), 93–101. <https://doi.org/10.36519/idcm.2024.332>
56. Triffault-Fillit C, Ferry T, Laurent F, Pradat P, Dupieux C, Conrad A, et al. Microbiologic epidemiology depending on time to occurrence of prosthetic joint infection: a prospective cohort study. *Clin Microbiol Infect*. 2019;25(3):353-358. doi:10.1016/j.cmi.2018.04.035.
57. Tubb CC, Polkowski GG, Krause B. Diagnosis and prevention of periprosthetic joint infections. *J Am Acad Orthop Surg*. 2020;28(8):e340-e348. doi:10.5435/JAAOS-D-18-00668.
58. Veerman CM, van der Bruggen T, van der Lubbe J, van den Kieboom J, Hellebrekers P, Wouthuyzen-Bakker M, et al. Assessment of antimicrobial mismatches in empirical treatment after DAIR following aseptic revision arthroplasty and association with failure of PJI treatment. *JAC Antimicrob Resist*. 2022;4(6):dlac124. doi:10.1093/jacamr/dlac124.
59. Weinstein EJ, Stephens-shields AJ, Newcomb CW, Silibovsky R, Nelson CL, Donnell JAO. Incidence, Microbiological Studies, and Factors Associated With Prosthetic Joint Infection After Total Knee Arthroplasty. *JAMA Netw Open* 2023;6:1–15. <https://doi.org/10.1001/jamanetworkopen.2023.40457>.
60. Wibowo, E.P. and Dilogu, I.H. (2021) 'The profile of hip and knee periprosthetic joint infection cases at dr. Cipto Mangunkusumo Central National Referral Hospital', *The Hip and Knee Journal*, 2(2), pp. 73–82. doi:10.46355/hipknee.v2i2.39.
61. Wouthuyzen-Bakker M, McNally M, Soriano A, Vogely HC. Cultures in periprosthetic joint infections: the imperfect gold standard. *EFORT Open Rev*. 2023;8(4):232-243. doi:10.1530/EOR-22-0115.
62. Xie B, Guo R, Yang X, Wan L, Yao W. Epidemiology and Drug Resistance Analysis of Mixed. *Surg Infect (Larchmt)* 2020;21. <https://doi.org/10.1089/sur.2019.276>.
63. Youssef, Y., Hättich, A. and Klepka, K.L. (2024) 'Periprosthetic joint infections – a scoping review', *Innovative Surgical Sciences*, 9(4), pp. 191–197. doi:10.1515/iss-2024-0016.

64. Yusuf E, Bramer W, Anas AA. Clinical outcomes of rifampicin combination therapy in staphylococcal prosthetic joint infection and prosthetic valve endocarditis: a systematic review and meta-analysis. *Int J Antimicrob Agents*. 2024;63:107015. doi:10.1016/j.ijantimicag.2023.107015.